BigDaniel,Re your last paragraph and the "bath water", here is...

BigDaniel,

Re your last paragraph and the "bath water", here is one that may not pop right back up like da ping pong ball...see AFR article excerpt....and to boot our CEO lives and works where we actually do our thing....I like hands ON, not hands off, it also speaks to how well a company manages (stretches) its' cash. Chalk and cheese these 2 imho.

Biotech CEOs hit the streets amid sector selloff

Yolanda Redrup Reporter

Mar 17, 2022 – 5.00am

Offshore chief executives of ASX-listed biotech companies are descending on
Australia this month, looking to shore up support amid the sector-wide sell-off.
Locally, listed biotech companies take their lead from their US counterparts and,
much like the Nasdaq Biotech Index, share price dives of 30 per cent-plus in the
past six months have been common across the sector.
Now, for the first time this year, CEOs from companies such as Chimeric
Therapeutics [https://www.copyright link/companies/healthcare-and-fitness/cancer-biotechchimeric-soars-50pc-on-debut-20210118-p56uwi], BCAL Diagnostics and Radiopharm
Theranostics are booking in-person meetings with local fund managers in an effort
to stem the slide.
Chimeric CEO Jennifer Chow completed a local roadshow last week and told The
Australian Financial Review it had been frustrating seeing the share price fall,
despite the company delivering on its prospectus promises.
Two of Paul Hopper’s companies are doing investor roadshows this month. Louie Douvis
“We’ve had phenomenal growth in the first 14 months. We’ve gone from one asset
to seven assets, and the share price does not reflect the value the company has,” she
said.
“When we had only one asset, we listed at 20¢, we spent most of the year trading
above 30¢, but now we have seven assets, and we’re trading below that.
“You shake your head because it doesn’t make a lot of sense ... but the sector will
eventually have a rebound, and we’ll see a better reflection of value.”
The roadshow was the first time Ms Chow, who is based in Canada, had been to
Australia since the company listed on the ASX in January 2021. She also had never
met Chimeric founder and executive chairman Paul Hopper in person.
Chimeric, which is a clinical-stage cell therapy company developing treatments for
cancers such as glioblastoma (brain cancer), colorectal and solid tumours, fetched
as much as 36¢ in July last year, but on Wednesday was trading at only 15¢.